



Title	Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban
Author(s)	坂井, 達弥
Citation	Nagasaki University (長崎大学), 博士(医学) (2017-09-20)
Issue Date	2017-09-20
URL	http://hdl.handle.net/10069/37827
Right	© 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This document is downloaded at: 2018-03-22T19:51:51Z

Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban

A Randomized Controlled Study

Tatsuya Sakai, MD, Masahiro Izumi, MD, Kenji Kumagai, MD, Kenichi Kidera, MD, Takayuki Yamaguchi, MD, Tomohiko Asahara, MD, Hideko Kozuru, MSc, Yuka Jiuchi, MSc, Masaaki Mawatari, MD, Makoto Osaki, MD, Satoru Motokawa, MD, and Kiyoshi Migita, MD

Abstract: We conducted a randomized clinical trial to compare the effectiveness of the A-V Impulse System foot pump for reducing the incidence of deep-vein thrombosis (DVT) after total knee arthroplasty (TKA) in patients under edoxaban thromboprophylaxis.

Patients undergoing primary TKA at our institution between September 2013 and March 2015 were enrolled after obtaining informed consent. The patients were randomized to use the foot pump (n=58) and not to use the foot pump (n=62). Both groups were given prophylactic edoxaban. Primary outcomes were any DVT as detected by bilateral ultrasonography up to postoperative day 10 (POD10) and pulmonary embolism (PE) up to POD28. The safety outcomes were bleeding and death of any cause up to POD28. Plasma D-dimer levels were measured before TKA and on POD10 after TKA. Immunoglobulin G (IgG)-class anti-PF4/heparin antibodies were measured using an IgG-specific enzyme-linked immunosorbent assay.

The incidences of any DVT up to POD28 were 31.0% and 17.7% in patients with or without the foot pump, respectively. The incidences of major bleeding up to POD28 were 5.1% and 4.8% in patients with or without the foot pump, respectively. Foot pump use did not significantly reduce the incidence of DVTs in patients undergoing TKA under edoxaban thromboprophylaxis. Although seroconversion of anti-PF4/heparin antibodies was confirmed in one-fourth of patients, the seroconversion rates did not differ between patients with (20.7%) or without (25.8%) foot pump use.

This study shows that the A-V Impulse system foot pump did not affect the incidence of DVT under edoxaban thromboprophylaxis in patients undergoing TKA. Seroconversion of anti-PF4/heparin antibodies was detected in a significant number of

patients who underwent TKA under antithrombotic prophylaxis using edoxaban.

(*Medicine* 95(1):e2247)

Abbreviations: CUS = compression US, DVT = deep vein thrombosis, HIT = heparin-induced thrombocytopenia, PE = pulmonary embolism, PF4 = platelet factor 4, POD = postoperative day, TKA = total knee arthroplasty.

INTRODUCTION

Total knee arthroplasty (TKA) is considered a successful procedure that improves quality of life for patients with end-stage knee joint arthritis.¹ However, the risk of venous thromboembolism (VTE), which can increase patient morbidity and mortality, is well recognized after TKA.² There are evidence-based guideline to prevent VTE,^{3,4} but the ideal prophylactic regimen has not been identified. The selection of a prophylactic regimen depends on a balance between efficacy and safety.⁵ Such regimens include low-molecular-weight heparin (LMWH), Xa inhibitors, and mechanical methods such as pneumatic foot compression.⁶ Several randomized trials have shown that the foot pump is an effective device for prophylaxis against thromboembolism in orthopedic patients.

Combined prophylactic modalities have been shown to improve the efficacy of single modalities in a variety of specialties.⁷⁻⁹ Edoxaban is an oral, selective, direct factor Xa (FXa) inhibitor that was approved as a thromboemboprophylactic agent in Japanese patients undergoing total joint arthroplasty.^{10,11} We therefore aimed to compare the frequency of thromboembolism after total knee replacement in patients who were randomized to be managed postoperatively with edoxaban thromboprophylaxis (both groups) with or without use of the foot pump. We also sought to evaluate these reversion rates of anti-PF4/heparin antibodies in these patients.

METHODS

Patient Enrollment

Consecutive patients (aged ≥ 20 years) undergoing knee replacement surgery for primary joint disease, including osteoarthritis (OA) and rheumatoid arthritis (RA) were enrolled. Exclusion criteria were the presence of predefined risk factors for bleeding, coagulation disorders, heart failure (New York Heart Association class III or IV), significant renal dysfunction (creatinine clearance < 30 mL/min), and abnormalities in biochemical measurements (aspartate

Editor: Samantha Martin.

Received: June 16, 2015; revised: November 19, 2015; accepted: November 13, 2015.

From the Department of Orthopedic Surgery, NHO Nagasaki Medical Center, Kubara, Omura/ Department of Molecular Immunology, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto, Nagasaki. Correspondence: Kiyoshi Migita, Clinical Research Center, NHO Nagasaki Medical Center, Kubara, Omura, Japan (E-mail: migita@nagasakimc.com).

Authors' contributions: TS, MI, MM, MO, SM, MK participated in the design of the study; HK, YJ analyzed the data; KKu, KKi, TY, TA collected the clinical data; all authors wrote the manuscript; all authors read and approved the final manuscript.

Funding: the study was supported by research grants research funds from the National Hospital Organization (NHO), Japan.

The authors have no conflicts of interest to disclose.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ISSN: 0025-7974

DOI: 10.1097/MD.0000000000002247

aminotransferase or alanine aminotransferase ≥ 5 times the upper limit of normal or total bilirubin ≥ 2 times the upper limit of normal). Patients were also excluded if they were scheduled to undergo bilateral joint replacement or reoperation, were unable to walk, or had uncontrolled cardiovascular disease.

Study Subjects

Between September 2013 and March 2015, a total of 126 patients were considered for inclusion in the study. As shown in the flow diagram (Figure 1), among these patients, 4 were excluded due to the exclusion criteria: 1 because of painful joints in the feet, which contraindicated use of the foot pump, and 3 because of contraindications for edoxaban. After enrollment, 2 patients were excluded after being lost to follow-up (Figure 1). The ethics committees at the Nagasaki Medical Center, where the study was conducted, approved the study protocol (No. 25004), and all patients signed informed consent forms.

Randomization

Randomization was performed on the day before the operation using sealed envelopes containing a slip indicating the allocation, which had been derived from a computer-generated sequence. Patients were given edoxaban alone or edoxaban plus use of the foot pump. Edoxaban was started 12 h after the operation. Patients were given low-dose edoxaban (15 mg once daily for patients <60 kg) or high-dose edoxaban (30 mg once daily for patients weighing ≥ 60 kg). Foot pump slippers were fitted for both feet in the recovery room, and the machine was activated. The nurses were advised to activate the foot pump whenever the patient was not bearing weight. The nurses routinely monitored the use of mechanical compression by checking it every 3 h until POD4. An alarm was also set to sound when the foot pump turned off or pressure did not appear. The pneumatic compression cycle was set at 20/min with a pressure of 130 mm Hg applied for 1 s. All patients wore bilateral knee-high antithromboembolic stockings. Physical therapy, range of motion exercises, and walking with partial weight bearing were usually initiated on POD4. The foot pump was continued until the start of physical therapy (POD4).




FIGURE 1. Flow Diagram of patient recruitment.

Outcome Measures

The primary effectiveness outcomes are overall venous thromboembolism (VTE) including asymptomatic DVTs up to POD10, symptomatic DVTs, and fatal/nonfatal pulmonary embolisms (PEs) up to POD28. All patients were checked for DVTs by ultrasonography (US) on POD10 or earlier if thrombosis was clinically suspected. DVT was diagnosed according to the presence of a venous thrombus detected by compression US (CUS), under the standardized method.^{12,13} DVTs were classified as proximal vein (popliteal vein and vein proximal to it) or a distal vein (any vein distal to the popliteal vein). PE was diagnosed according to the presence of intraluminal filling defect detected by computed tomography of the chest. The outcomes for safety were the bleeding and death from all causes up to POD28. Major bleeding was defined as wound hematoma or hemorrhage occurring at a critical site and bleeding required for >2 units of red blood cell concentrates. Minor bleeding was defined as bleeding that did not fulfill the criteria for major.

Blood Sampling

Serum samples were obtained before the operation and at POD10 and were stored at -30°C . A enzyme-linked immunosorbent assay (ELISA) kit (GTI Diagnostics, Waukesha, WI) was used to measure the IgG-class antiheparin-platelet factor 4 (PF4) antibody (HIT antibody) according to the manufacturer's instructions. ELISA reactivity (optical density, OD) was expressed relative to a standard control. The cutoff value was set at 0.40 optical density (OD) units. We defined seroconversion as a positive test result on POD10 corresponding to a negative result before surgery if the patient's blood sample on POD 10 was positive and had a 2-fold or more increase in OD, as defined in a previous study.¹⁴

Statistical Analysis

Discrete variables were compared using χ^2 tests and continuous variables using Mann–Whitney tests. Plasma D-dimer levels are expressed as means (\pm SD) or medians (interquartile ranges) in Figure 2. Boxplots display the lower hinge defined as the 25th percentile, the middle hinge as the 50th percentile, and the upper hinge as the 75th percentile. All reported *P* values were 2-tailed. All data processing and analyses were performed using the Statistical Analysis System (SAS) and SPSS version 18 software (SPSS, Chicago, IL).

RESULTS

Patient Demographic Data

The characteristics of the study population (total patients 117; RA 23, OA 94) undergoing TKA are presented in Table 1. The risk of VTE in each patient was individually assessed based on the presence of the risk factors listed in Table 1, including, age, sex, and comorbidities. Of the 120 patients who were ultimately randomized, 58 used the foot pump and edoxaban, and 62 used edoxaban alone. The 2 groups were comparable in terms of their baseline characteristics and the operations they underwent (Table 2). The demographic data showed some differences between patients with or without the foot pump, but the differences did not reach statistical significance. All patients underwent pharmacological thromboprophylaxis with edoxaban. The mean doses of edoxaban were 20.4 ± 7.3 mg for 11.6 ± 1.7 days in patients with the foot pump and 21.3 ± 7.5 mg for 11.3 ± 2.0 days in those without the foot pump. Three patients received aspirin because of their ischemic




FIGURE 2. Preoperative (before) and postoperative day 10 (after) plasma D-dimer levels in patients with or without use of foot pump. *P* values were calculated by the Mann–Whitney *U* test.

heart disease (Table 2). Aspirin administration was stopped 7 days before operation and started again on POD3 in all 3 patients. There were no statistically significant differences in the doses of edoxaban use between the 2 groups.

Incidence of Postoperative VTE

The rate of all DVT appearances up to POD10 was 31.0% (18 patients) (Table 3). Symptomatic DVTs occurred in 3 patients (5.2%) with the foot pump, and 17.7% (11 patients), with symptomatic DVTs occurring and in 1 patient (1.6%) without the foot pump. The locations of the thrombi are shown in Table 2. Most thrombi were located in the distal veins in both groups. Comparisons were also performed to identify predictors of DVTs. The demographic data showed some differences in doses of edoxaban between patients with or without DVT (Table 4). The 2 groups were otherwise similar. When we compared the incidence of postoperative total DVTs between the patients with and without use of the foot pump (Table 5), there was no significant difference in the incidence of DVTs between the 2 groups (*P* = 0.089; odds ratio [OR] 2.09, 95% confidence interval [CI] 0.89–4.87). Hence, use of the foot pump did not prevent the occurrence of DVTs.

Incidence of Postoperative Bleeding

Safety analysis showed that the incidences of major bleeding up to POD28 in patients with or without the foot pump were 5.1% (n = 3) and 4.8% (n = 3), respectively. No fatal bleeding was observed (Table 6). Among the 6 patients with major bleeding, edoxaban administration was ceased at POD4 in 1 patient. It was continued in the remaining 5 patients. We also compared the incidence of any bleeding between patients with or without the foot pump (Table 5). There was no significant difference in

TABLE 1. Baseline Characteristics of the Patients Receiving Total Knee Arthroplasty

	Total Knee Arthroplasty n = 120
Gender (male/female)	20/100
Age, years	
Mean ± SD	73.7 ± 6.7
Range	54–85
Height, cm	151.7 ± 7.1
Weight, kg	61.3 ± 10.7
BMI	26.6 ± 4.1
RA/OA	23/97
History of venous thrombosis, no. (%)	6 (5.0%)
Comorbidities	
Hypertension	81 (67.5%)
Ischemic heart disease	6 (5.0%)
Diabetes	27 (22.5%)
Cerebrovascular disease	10 (8.3%)
Operation time (min)	
Mean ± SD	93.9 ± 23.2
General anesthesia (%)	120 (100%)
Use of elastic stocking, no. (%)	120 (100%)
Use of tourniquet, no. (%)	120 (100%)
Use of cement, no. (%)	120 (100%)
Prophylaxis	
Edoxaban (duration)	20.9 ± 7.4 mg/day (11.4 ± 1.8 days)

BMI = body mass index, OA = osteoarthritis, RA = rheumatoid arthritis, SD = standard deviation.

TABLE 2. Baseline Characteristics of the Patients With or Without Foot Pump

	n = 120		P Value
	Foot Pump + n = 58	Foot Pump – n = 62	
Gender (male/female)	9/49	11/51	0.7438
Age, years			
Mean ± SD	73.0 ± 7.2	74.3 ± 6.1	0.4282
Range	54–84	57–85	
Height, cm	151.2 ± 7.2	152.0 ± 7.1	0.3581
Weight, kg	60.1 ± 11.1	62.4 ± 10.1	0.3021
BMI	26.2 ± 4.0	27.1 ± 4.2	0.3608
RA/OA	12/46	11/51	0.6818
History of venous thrombosis, no. (%)	3 (5.2%)	3 (4.8%)	0.9332
Comorbidities			
Hypertension	39 (67.2%)	42 (67.7%)	0.9533
Ischemic heart disease	4 (6.9%)	2 (3.2%)	0.3565
Diabetes	17 (29.3%)	10 (16.1%)	0.084
Cerebrovascular disease (use of aspirin)	6 (10.3%) (1)	4 (6.5%) (2)	0.4406
Operation time, (min)			
Mean ± SD	96.8 ± 24.5	91.5 ± 22.0	0.1257
Prophylaxis			
Edoxaban (duration)	20.4 ± 7.3 mg/day (11.6 ± 1.7 days)	21.3 ± 7.5 mg/day (11.3 ± 2 days)	0.5224

BMI = body mass index, OA = osteoarthritis, RA = rheumatoid arthritis, SD = standard deviation.

the incidence of bleeding between these 2 groups ($P = 0.451$; OR 0.64, 95%CI 0.20–2.06).

Changes in Plasma D-Dimer Levels

As shown in Figure 2, preoperative D-dimer levels (mean ± SD) did not differ significantly in patients with the foot pump ($1.7 \pm 1.9 \mu\text{g/mL}$) and those without the foot pump ($2.4 \pm 3.3 \mu\text{g/mL}$). However, the D-dimer levels were significantly elevated on POD10 compared with those on POD0, although there was no significant difference in postoperative D-dimer levels between patients with ($8.2 \pm 3.8 \mu\text{g/mL}$) or without ($9.5 \pm 7.2 \mu\text{g/mL}$) the foot pump.

TABLE 3. Incidences of Primary Effectiveness Outcomes in Patients Receiving TKA

	Foot Pump (+) n = 58 (%)	Foot Pump (–) n = 62 (%)
All venous thromboembolism	18 (31.0)	11 (17.7)
symptomatic DVT (up to POD28)	3 (5.2)	1 (1.6)
Distal	3 (5.2)	1 (1.6)
Proximal	0	0
Nonsymptomatic DVT (up to POD10)	15 (25.9)	10 (16.1)
Distal	15 (25.9)	10 (16.1)
Proximal	0	0
PE (up to POD28)	0	0

DVT = deep vein thrombosis, PE = pulmonary embolism, POD = postoperative day, TKA = total knee arthroplasty.

Seroconversion of IgG-Class PF4/Heparin Antibody

The seroconversion of anti-PF4/heparin antibody was confirmed in 20.7% (12/58) of patients with the foot pump and in 25.8% (16/62) of those without the foot pump under thromboprophylaxis with edoxaban (Table 7). There was no difference in the seroconversion rate between patients with or without the foot pump. The seroconversion of anti-PF4/heparin antibodies was not significantly associated with the occurrence of DVT or bleeding (Table 8). There was no significant difference in postoperative platelet counts between patients with or without seroconversion of anti-PF4/heparin antibodies (Figure 3). Additionally, no patients had postoperative thrombocytopenia ($<10.0 \times 10^4/\text{mL}$) as well as definitive heparin-induced thrombocytopenia (data not shown).

DISCUSSION

Patients who undergo orthopedic operations such as a total joint replacement on the lower extremity are at high risk for developing thromboembolic disease.¹⁵ Without prophylaxis after total knee replacement, the prevalence of DVT has been reported to be as high as 50%.¹⁶ PE has been documented in 2% to 5% of patients not treated prophylactically, and fatal PE has been reported in 1% to 2%.¹⁷ With such high morbidity and mortality rates associated with thromboembolic disease, a prophylactic regimen after total knee replacement is essential.¹⁸ In recent years, there has been significant progress toward more effective and practical thromboprophylaxis for patients undergoing joint replacement surgery, including LMWHs and oral agents (selective factor X inhibitors) such as rivaroxaban, apixaban, and edoxaban.^{10,19–21} Also, the use of mechanical devices such as a venous calf or foot pump—either alone or in combination with chemical prophylaxis—can reduce the rate of venous thromboembolism.²² Mechanical devices such as the

TABLE 4. Baseline Characteristics of the Patients With or Without DVT

	n = 120		P Value
	DVT + n = 29	DVT – n = 91	
Gender (male/female)	3/26	17/74	0.2942
Age, years			
Mean ± SD	74.2 ± 6.3	73.5 ± 6.8	0.5971
Range	58–83	54–85	
Height, cm	151.5 ± 7.0	151.7 ± 7.2	0.8661
Weight, kg	61.1 ± 11.3	61.4 ± 10.5	0.9731
BMI	26.5 ± 4.1	26.7 ± 4.1	0.9146
RA/OA	7/22	16/75	0.4348
History of venous thrombosis, no. (%)	2 (6.9%)	4 (4.4%)	0.5905
Comorbidities			
Hypertension	18 (62.1%)	63 (69.2%)	0.4733
Ischemic heart disease	1 (3.5%)	5 (5.5%)	0.6597
Diabetes	6 (20.7%)	21 (23.1%)	0.7886
Cerebrovascular disease	2 (6.9%)	8 (8.8%)	0.7479
Operation time (min)			
Mean ± SD	90.7 ± 23.2	94.9 ± 23.2	0.1754
Prophylaxis			
Edoxaban (duration)	18.1 ± 6.2 mg/day (10.5 ± 2.8 days)	21.8 ± 7.5 mg/day (11.7 ± 1.3 days)	0.0197

BMI = body mass index, DVT = deep vein thrombosis, OA = osteoarthritis, RA = rheumatoid arthritis, SD = standard deviation.

TABLE 5. Incidences of any DVT and Bleeding in Patients Receiving TKA

Events	Foot Pump (+) n = 58	Foot Pump (–) n = 62	Odds ratio (95% CI)	P Value
DVT (%)	18 (31.0)	11 (17.7)	2.086 (0.894–4.872)	0.0892
Bleeding (%)	5 (8.6)	8 (12.9)	0.637 (0.197–2.057)	0.4507

CI = confidence interval, DVT = deep vein thrombosis, TKA = total knee arthroplasty.
 Five patients with bleeding in foot pump (+) group were classified as major bleeding (3) and minor bleeding (2).
 Eight patients with bleeding in foot pump (–) group were classified as major bleeding (3) and minor bleeding (5).

venous foot pump have been shown to be effective methods of prophylaxis.²³

In this study, we evaluated the prophylactic effect of pneumatic foot compression under thromboprophylaxis with edoxaban in patients undergoing TKA. We found that the incidence of DVT after TKA in the combined prophylaxis group (A-V impulse pneumatic compression device and

edoxaban) was 31.0% and that with edoxaban alone (without the foot pump) was 17.7%. Hence, no argument could be made for the effectiveness of mechanical devices as prophylaxis against postoperative DVT in patients given edoxaban. Our results were disappointing in that use of the foot pump could not reduce the incidence of DVT in combination with chemical prophylaxis (edoxaban). The incidences of any DVT in our

TABLE 6. Incidences of Bleeding in Patients Receiving TKA

	Foot Pump (+) n = 58 (%)	Foot Pump (–) n = 62 (%)	OR (95% CI)	P
All bleeding events no. (%)	5 (8.6)	8 (12.9)	0.637 (0.197–2.057)	0.4507
Major bleeding	3 (5.1)	3 (4.8)	1.073 (0.208–5.539)	0.9332
Wound hematoma	2 (3.4)	2 (3.2)		
Bleeding requiring of ≥ 2 units of transfusion	1 (1.7)	1 (1.6)		
Bleeding contributing to death	0	0		
Minor bleeding	2 (3.4)	5 (8.0)		

CI = confidence interval, OR = odds ratio, TKA = total knee arthroplasty.

TABLE 7. Serconversion Rates of Anti-PF4/Heparin Antibodies Patients With or Without Foot Pump

	Foot Pump (+) n = 58 (%)	Foot Pump (-) n = 62 (%)	P Value
Seroconversion rate (%)	12 (20.7)	16 (25.8)	0.5078
OD units (mean ± SD) POD 0	0.156 ± 0.092	0.210 ± 0.305	0.5115
OD units (mean ± SD) POD 10	0.341 ± 0.410	0.504 ± 0.658	0.1158
OD units (≥ 1.4)	2 (3.4)	6 (9.7)	0.1716

OD = optical density, PF4 = platelet factor 4, SD = standard deviation.

TABLE 8. Incidences of Any DVT and Bleeding in Patients Receiving TKA

Events	HIT Ab (+) n = 28	HIT Ab (-) n = 92	Odds Ratio (95% CI)	P Value
DVT (%)	7 (24.1)	22 (23.9)	1.061 (0.398–2.827)	0.9064
Bleeding (%)	5 (17.9)	8 (8.7)	2.283 (0.698–7.461)	0.1720

CI = confidence interval, DVT = deep vein thrombosis, HIT = heparin-induced thrombocytopenia, TKA = total knee arthroplasty.

study were relatively high compared with those in other clinical trials using edoxaban. However, adaptation of clinical trials data in highly selected patients to a “real-world” population could be tied to some difficulties. It is possible that TKA is postoperatively resistant to mechanical thromboprophylaxis. Another interpretation is that US is subject to considerable variation,²⁴ although a recent systematic review suggested that US provides an accurate postoperative diagnosis of DVT in asymptomatic orthopedic patients. Previous studies suggested that mechanical and pharmacological methods applied for VTE prophylaxis are both effective and, when used in combination,

have synergistic effects.²⁵ Although there are a number of intermittent pneumatic compression systems, little evidence is available at present that differentiates these methods based on VTE prevention. It was demonstrated that calf–thigh pneumatic compression was more effective than plantar compression for reducing thigh swelling during the early postoperative stage.²⁶ These differences in pneumatic compression devices may contribute to the different intervention-related outcomes.

Kakkos *et al* reported that combined intermittent pneumatic leg compression and pharmacological prophylaxis significantly reduced the incidence of DVT compared with leg




FIGURE 3. Preoperative (before) and postoperative day 10 (after) platelet counts in patients with or without the seroconversion of HIT antibodies. P values were calculated by the Mann–Whitney U test.

compression or pharmacological prophylaxis alone. The efficacy of intermittent pneumatic compression combined with LMWH compared with LMWH alone was demonstrated in patients undergoing total hip arthroplasty.²⁷ Meta-analysis concluded that leg compression augments the efficacy of pharmacological prophylaxis in preventing DVT in both TKA and THA.²⁸ Whereas other studies could not demonstrate the effectiveness of mechanical prophylaxis in preventing DVT compared to the pharmacological prophylaxis.^{29,30} Although evidence from nonorthopedic patient populations suggests an advantage for combined mechanical and pharmacological prophylaxis, there are insufficient data to conclude whether combined modalities are better than either anticoagulants or mechanical compression used alone.

Another interesting finding in this study was that seroconversion of the IgG-class anti-PF4/heparin antibody occurred in a substantial number of patients under edoxaban prophylaxis. Fondaparinux, another Xa inhibitor, is occasionally associated with anti-PF4/heparin antibodies.³² It was demonstrated that the frequency of forming anti-PF4/heparin antibodies was the same for patients receiving fondaparinux or enoxaparin.³¹ However, HIT rarely develops in patients on fondaparinux.³² The failure of these antibodies to cause HIT has been attributed to the inability of fondaparinux to react with PF4.³³ Previously, we reported that the seroconversion rate of anti-PF4/heparin antibodies was 24.5% in patients given fondaparinux for pharmacological thromboprophylaxis.³⁴ Compared with these data, the seroconversion rate of anti-PF4/heparin antibodies (23.5%) in patients given edoxaban for pharmacological thromboprophylaxis are close to those in patients given fondaparinux. The seroconversion of the IgG-class anti-PF4/heparin antibody, however, seemed not to be a risk factor for DVT or HIT in patients given edoxaban. Because of their molecular structures as Xa inhibitors, these newer anticoagulants could not interact with PF4 or be subjected to PF4 binding to platelets.³⁵ Alternatively, edoxaban is a bystander, which together with other postoperative negatively charged polyanions, such as heparin sulfate, trigger an immune reaction and production of anti-PF4-heparin antibodies.³⁶

LIMITATIONS

One major limitation of the present study is that this quasi-randomized controlled trial may have several biases. It is impossible to blind patients or clinicians when using physical interventions. For sample size calculation, we used our previously published data from Japanese patients under recent thromboprophylaxis to determine a DVT rate of ~24.3% following TKA.³⁷ Based on these assumptions, we primarily calculated that we needed 126 patients with the foot pump and 126 patients without it to confirm a reduction in DVTs (relative risk 0.43) as demonstrated in a recent system review³⁹ at an α error of 0.05 and a β error of 0.80. However, we could not accumulate a sufficient sample size, and there is an undeniable possibility of the study being underpowered. The credibility of our finding that the foot pump was not effective for preventing DVTs in patients who had undergone TKA should be assessed in light of current evidence.³⁸ According to the Bayesian credibility assessment by Matthews *et al*,³⁹ to determine the credibility of our findings in the light of existing evidence, the odds ratio had to be <0.96 before the results of our study could be considered credible. However, the calculated odds ratio in the present study was 2.1 and there was significant discrepancy. We are also concerned about the insufficient sample size.

Additional limitations include the lack of sham devices and placebo use in the study. Also, the duration of mechanical prophylaxis was relatively limited (4 days) in our study because most of the enrolled patients underwent early mobilization. Most asymptomatic DVTs detected by ultrasonography were located distally, for which the diagnostic accuracy of ultrasonography could be lower than for proximal DVT. However, ultrasonography yielded a better diagnostic performance even in patients with asymptomatic DVT when performed by trained sonographers under standardized examination procedures.

In conclusion, our randomized controlled study demonstrated that combined pharmacological (edoxaban) and mechanical prophylaxis (a foot pump) did not reduce the incidence of DVT in patients who had undergone TKA surgery compared with edoxaban alone. Further research should focus on the efficacy of more recent intermittent compression with anticoagulants, such as factor Xa inhibitors. Seroconversion of anti-PF4/heparin antibodies was detected in a substantial number of patients who underwent TKA and who were under antithrombotic prophylaxis using edoxaban.

REFERENCES

1. Ethgen O, Bruyère O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty: A qualitative and systematic review of the literature. *J Bone Joint Surg Am.* (86–A):2004:963–974.
2. Kanchanabatt B, Stapanavatr W, Meknavin S, et al. Systematic review and meta-analysis on the rate of postoperative venous thromboembolism in orthopaedic surgery in Asian patients without thromboprophylaxis. *Br J Surg.* 2011;98:1356–1364.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008; 133(6 Suppl):381S–453S.
4. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141:e278S–e325S.
5. Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. *J Bone Joint Surg Am.* 2013;95:1801–1811.
6. Lachiewicz PF. Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplasty. *Orthopedics.* 2009;32:74–78.
7. Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement: Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. *J Bone Joint Surg Br.* 1999;81:654–659.
8. Westrich GH, Sculco TP. Prophylaxis against deep venous thrombosis after total knee arthroplasty: Pneumatic plantar compression and aspirin compared with aspirin alone. *J Bone Joint Surg Am.* 1996;78: 826–834.
9. Kakkos SK, Warwick D, Nicolaidis AN, et al. Combined (mechanical and pharmacological) modalities for the prevention of venous thromboembolism in joint replacement surgery. *J Bone Joint Surg Br.* 2012;94:729–734.
10. Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. *J Thromb Haemost.* 2010;8:2458–2468.
11. Fuji T, Fujita S, Kawai Y, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. *Thromb Res.* 2014;133:1016–1022.

12. Kory PD, Pellecchia CM, Shiloh AL, et al. Accuracy of ultrasonography performed by critical care physicians for the diagnosis of DVT. *Chest*. 2011;139:538–542.
13. Schwarz T, Schmidt B, Schmidt B, et al. Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis. *Clin Appl Thromb Hemost*. 2002;8:45–49.
14. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. *J Thromb Haemost*. 2010;8:504–512.
15. Schiff RL, Kahn SR, Shrier I, et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. *Chest*. 2005;128:3364–3371.
16. Choi BY, Huo MH. Venous thromboembolism following total knee replacement. *J Surg Orthop Adv*. 2007;16:31–35.
17. White RH, Henderson MC. Risk factors for venous thromboembolism after total hip and knee replacement surgery. *Curr Opin Pulm Med*. 2002;8:365–371.
18. Lewis CG, Inneh IA, Schutzer SF, et al. Evaluation of the first-generation AAOS clinical guidelines on the prophylaxis of venous thromboembolic events in patients undergoing total joint arthroplasty: experience with 3289 patients from a single institution. *J Bone Joint Surg Am*. 2014;96:1327–1332.
19. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med*. 2002;162:1833–1840.
20. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008;358:2776–2786.
21. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *N Engl J Med*. 2009;361:594–604.
22. Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. *Cochrane Database Syst Rev*. 2008;4:CD005258.
23. Warwick D, Harrison J, Glew D, et al. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement A prospective, randomized trial. *J Bone Joint Surg Am*. 1998;80:1158–1166.
24. Wheeler HB, Hirsh J, Wells P, et al. Diagnostic tests for deep vein thrombosis. *Clinical usefulness depends on probability of disease* *Arch Intern Med*. 1994;154:1921–1928.
25. Colwell CW Jr, Froimson MI, Anseth SD, et al. A mobile compression device for thrombosis prevention in hip and knee arthroplasty. *J Bone Joint Surg Am*. 2014;96:177–183.
26. Fujisawa M, Naito M, Asayama I, et al. Effect of calf-thigh intermittent pneumatic compression device after total hip arthroplasty: comparative analysis with plantar compression on the effectiveness of reducing thrombogenesis and leg swelling. *J Orthop Sci*. 2003;8:807–811.
27. Pitto RP, Hamer H, Heiss-Dunlop W, et al. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. *J Bone Joint Surg Br*. 2004;86:639–642.
28. He ML, Xiao ZM, Lei M, et al. Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty. *Cochrane Database Syst Rev*. 2014;7:CD008207.
29. Warwick D, Harrison J, Whitehouse S, et al. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. *J Bone Joint Surg Br*. 2002;84:344–350.
30. Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. *J Bone Joint Surg Br*. 199;81:654–659.
31. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. *Blood*. 2005;1:3791–3796106.
32. Salem M, Elrefai S, Shrit MA, et al. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. *Thromb Haemost*. 2010;104:1071–1072.
33. Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. *Thromb Res*. 2008;122:211–220.
34. Motokawa S, Torigoshi T, Maeda Y, et al. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. *BMC Musculoskelet Disord*. 2011;12:22.
35. Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. *Blood*. 2014;124:2442–2449.
36. Brandt S, Krauel K, Gottschalk KE, et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. *Thromb Haemost*. 2014;112:53–64.
37. Migita K, Bito S, Nakamura M, et al. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study. *Arthritis Res Ther*. 2014;16:R154.
38. Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. *Circulation*. 2013;128:1003–1020.
39. Matthews RAJ. Methods for assessing the credibility of clinical trial outcomes. *Drug Inform J*. 2001;35:1469–1478.